Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
TR-4 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
TR-4: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Platelet Rich Plasma-Derived Exosomes(Institute for the Study of Urological Diseases, Greece) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Platelet Rich Plasma-Derived Exosomes(Institute for the Study of Urological Diseases, Greece): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clin
9 min read
Autologous Bone Marrow Mononuclear Cell Transfusion(Vinmec Research Institute of Stem Cell and Gene Technology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Autologous Bone Marrow Mononuclear Cell Transfusion(Vinmec Research Institute of Stem Cell and Gene Technology): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence
9 min read
tRNA-derived fragments-antisense oligonucleotides-exosomes(Affiliated Hospital of Nantong University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
tRNA-derived fragments-antisense oligonucleotides-exosomes(Affiliated Hospital of Nantong University): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review cov
9 min read
Umbilical Cord-Derived Mesenchymal Stem Cells (Yeditepe University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Umbilical Cord-Derived Mesenchymal Stem Cells (Yeditepe University): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, lice
9 min read
YMP Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
YMP: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
XKZ2305 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
XKZ2305: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Allogenic mesenchymal stem cells isolated from adipose tissue(Warszawski Uniwersytet Medyczny) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Allogenic mesenchymal stem cells isolated from adipose tissue(Warszawski Uniwersytet Medyczny): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers cli
9 min read
Ledipasvir/Sofosbuvir in Beta-Thalassemia: NCT03961828 Clinical Landscape Report 2026
28 September 2026
NCT03961828 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sapablursen in Beta-Thalassemia: NCT04059406 Clinical Landscape Report 2026
28 September 2026
NCT04059406 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Human apotransferrin(Prothya Biosolutions) in Beta-Thalassemia: NCT03993613 Clinical Landscape Report 2026
28 September 2026
NCT03993613 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Luspatercept-AAMT in Beta-Thalassemia: NCT04064060 Clinical Landscape Report 2026
28 September 2026
NCT04064060 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.